Precursor-Directed Diversification of Cyclic Tetrapeptidic Pseudoxylallemycins.
Huijuan GuoAlexander SchmidtPhilipp StephanLuka RagužDaniel BragaMarcel KaiserHans-Martin DahseChristiane WeigelGerald LacknerChristine BeemelmannsPublished in: Chembiochem : a European journal of chemical biology (2018)
Cyclic peptides containing non-proteinogenic amino acids often exhibit a broad bioactivity spectrum and many have entered clinical trials with good prospects for drug development. We recently reported the discovery of six cyclic tetrapeptides, pseudoxylallemycins A-F (1-6), from a termite-associated Pseudoxylaria sp. X802. These compounds contain a rare O-homoallenyl-l-tyrosine moiety and show promising antimicrobial activity against the Gram-negative pathogenic bacterium Pseudomonas aeruginosa. To perform more detailed structure-activity studies, we pursued a precursor-directed diversification strategy. Herein, we report the purification, identification, and testing of 21 new pseudoxylallemycin derivatives.
Keyphrases
- gram negative
- multidrug resistant
- pseudomonas aeruginosa
- amino acid
- clinical trial
- small molecule
- cystic fibrosis
- acinetobacter baumannii
- high throughput
- drug resistant
- randomized controlled trial
- biofilm formation
- current status
- case control
- staphylococcus aureus
- open label
- phase ii
- study protocol
- structure activity relationship
- phase iii
- placebo controlled